TWI724018B - 用於癌症治療之組合療法 - Google Patents

用於癌症治療之組合療法 Download PDF

Info

Publication number
TWI724018B
TWI724018B TW105126680A TW105126680A TWI724018B TW I724018 B TWI724018 B TW I724018B TW 105126680 A TW105126680 A TW 105126680A TW 105126680 A TW105126680 A TW 105126680A TW I724018 B TWI724018 B TW I724018B
Authority
TW
Taiwan
Prior art keywords
irinotecan
cancer
administered
inhibitor
days
Prior art date
Application number
TW105126680A
Other languages
English (en)
Chinese (zh)
Other versions
TW201713312A (zh
Inventor
莎拉Ｆ 布蘭奇提
強納森 波西爾 菲茲格拉德
戴爾Ｃ 卓蒙德
維克特 摩由
Original Assignee
英商益普生生物製藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56801880&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI724018(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 英商益普生生物製藥有限公司 filed Critical 英商益普生生物製藥有限公司
Publication of TW201713312A publication Critical patent/TW201713312A/zh
Application granted granted Critical
Publication of TWI724018B publication Critical patent/TWI724018B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW105126680A 2015-08-20 2016-08-19 用於癌症治療之組合療法 TWI724018B (zh)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201562207709P 2015-08-20 2015-08-20
US201562207760P 2015-08-20 2015-08-20
US62/207,760 2015-08-20
US62/207,709 2015-08-20
US201562269511P 2015-12-18 2015-12-18
US201562269756P 2015-12-18 2015-12-18
US62/269,756 2015-12-18
US62/269,511 2015-12-18
US201662308924P 2016-03-16 2016-03-16
US62/308,924 2016-03-16
US201662323422P 2016-04-15 2016-04-15
US62/323,422 2016-04-15

Publications (2)

Publication Number Publication Date
TW201713312A TW201713312A (zh) 2017-04-16
TWI724018B true TWI724018B (zh) 2021-04-11

Family

ID=56801880

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105126680A TWI724018B (zh) 2015-08-20 2016-08-19 用於癌症治療之組合療法

Country Status (18)

Country Link
US (4) US9895365B2 (OSRAM)
EP (1) EP3337467B1 (OSRAM)
JP (1) JP7042739B2 (OSRAM)
KR (1) KR20180037210A (OSRAM)
CN (1) CN108348480A (OSRAM)
AU (1) AU2016309002B2 (OSRAM)
CA (1) CA2992789A1 (OSRAM)
ES (1) ES2848118T3 (OSRAM)
HK (1) HK1257216A1 (OSRAM)
IL (1) IL257147B (OSRAM)
MX (1) MX381475B (OSRAM)
PL (1) PL3337467T3 (OSRAM)
PT (1) PT3337467T (OSRAM)
RU (1) RU2760185C2 (OSRAM)
SG (1) SG10201913073YA (OSRAM)
SI (1) SI3337467T1 (OSRAM)
TW (1) TWI724018B (OSRAM)
WO (2) WO2017031445A1 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103948545B (zh) 2004-05-03 2017-10-03 益普生生物制药公司 用于药物输送的脂质体
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
EP3229802A1 (en) * 2014-12-09 2017-10-18 Ipsen Biopharm Ltd. Treatment of breast cancer with liposomal irinotecan
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
SG10201913073YA (en) 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
SG10201913077QA (en) 2015-08-21 2020-02-27 Ipsen Biopharm Ltd Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
CN114073678A (zh) 2015-10-16 2022-02-22 易普森生物制药有限公司 稳定喜树碱药物组合物
BR112019007844A2 (pt) 2016-11-02 2019-07-16 Ipsen Biopharm Ltd tratamento de câncer gástrico usando terapias de combinação compreendendo irinotecano lipossômico, oxaliplatina, 5-fluoroacila (e leucovorina)
TWI879716B (zh) 2017-05-09 2025-04-11 美商提薩羅有限公司 治療癌症的組合療法
CN110913911A (zh) 2017-05-18 2020-03-24 特沙诺有限公司 用于治疗癌症的组合疗法
GB201709076D0 (en) * 2017-06-07 2017-07-19 Inst Of Cancer Research: Royal Cancer Hospital Parp inhibitors for use in methods of treating cancer
SG11202002862RA (en) 2017-09-30 2020-04-29 Tesaro Inc Combination therapies for treating cancer
KR20200067164A (ko) 2017-10-06 2020-06-11 테사로, 인코포레이티드 조합 요법 및 그의 용도
US20200289613A1 (en) * 2017-11-04 2020-09-17 Aravive Biologics, Inc. Methods of treating metastatic cancers using axl decoy receptors
JP2021510701A (ja) * 2018-01-12 2021-04-30 プロリンクス エルエルシー 併用投与の毒性を最小化するためのプロトコルおよび検証用のイメージング剤
WO2019200382A1 (en) * 2018-04-13 2019-10-17 The Board Of Regents Of University Of Texas System Nanoparticle compositions and methods of use of parp inhibitor for treatment of cancer
CN112292133A (zh) * 2018-06-01 2021-01-29 百济神州有限公司 在胃癌治疗中的parp抑制剂维持疗法
WO2020124070A1 (en) * 2018-12-14 2020-06-18 Athenex HK Innovative Limited Therapeutic combinations of orally administered irinotecan and a p-gp inhibitor for the treatment of cancer
CN114053271B (zh) * 2020-07-30 2024-05-07 江苏天士力帝益药业有限公司 一种含有tsl-1502m的药物组合物及其应用
CN114053415B (zh) * 2020-07-30 2024-06-18 江苏天士力帝益药业有限公司 Tsl-1502复方药物组合
CA3216716A1 (en) * 2021-05-03 2022-11-10 Tim BERGBREDE Composition comprising an inhibitor of mitochondrial transcription
RU2769543C2 (ru) * 2021-07-21 2022-04-01 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ оценки первичного ответа на проводимую комбинированную химиотерапию спорадического рака яичников III и IV стадий
CN114259569B (zh) * 2021-12-30 2024-02-27 中山大学附属第八医院（深圳福田） 基于伊立替康和尼拉帕利的超分子纳米药物的制备方法和应用
EP4209217A1 (en) * 2022-01-11 2023-07-12 Fundación Profesor Novoa Santos Method for the treatment of brca1/2 mutated cancer
CN120225196A (zh) 2022-11-21 2025-06-27 富士胶片株式会社 含有内含拓扑替康或其盐的脂质体组合物及dna损伤修复抑制剂的组合药物

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
JPH0720857B2 (ja) 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5538954A (en) 1994-06-24 1996-07-23 A/S Dumex (Dumex Ltd.) Salts of tetracyclines
US5783568A (en) 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
DE19605024A1 (de) 1996-01-31 1997-08-07 Schering Ag Neue selektive Taxane, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
WO1998017256A1 (en) 1996-10-22 1998-04-30 Dmitri Kirpotin Compound-loaded liposomes and methods for their preparation
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6787132B1 (en) 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
US6355268B1 (en) 1998-09-16 2002-03-12 Alza Corporation Liposome-entrapped topoisomerase inhibitors
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
WO2000066125A1 (en) 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
WO2001056548A2 (en) 2000-02-04 2001-08-09 Lipoxen Technologies Limited Liposomes composition produced by a dehydration-rehydration process
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
DK1286671T3 (da) 2000-05-15 2006-07-17 Celgene Corp Sammensætninger til behandling af colorektal cancer hvilke indeholder thalidomid og irinotecan
CN1245977C (zh) 2000-06-30 2006-03-22 英耐克斯药品股份有限公司 脂质体抗肿瘤药物及其使用
TWI283575B (en) 2000-10-31 2007-07-11 Eisai Co Ltd Medicinal compositions for concomitant use as anticancer agent
NZ528523A (en) 2001-03-26 2006-03-31 Alza Corp Liposome composition for improved intracellular delivery of a therapeutic agent
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
WO2003030864A1 (en) 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
EP1408973A2 (en) 2001-07-23 2004-04-21 Epidauros Biotechnologie AG Means and methods for improved treatment of cancer based on mrp1
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2486007C (en) 2002-05-15 2011-11-22 California Pacific Medical Center Delivery of nucleic acid-like compounds
EP2431385A3 (en) 2002-05-31 2012-07-04 Morphotek, Inc. Combination therapy with chlorotoxin
AU2003296897A1 (en) 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
MXPA05012723A (es) 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
CN103948545B (zh) 2004-05-03 2017-10-03 益普生生物制药公司 用于药物输送的脂质体
MXPA06013874A (es) 2004-06-01 2007-04-25 Terumo Corp Formulacion de irinotecan.
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
US7842676B2 (en) 2005-10-25 2010-11-30 Celator Pharmaceuticals, Inc. Fixed ratio drug combination treatments for solid tumors
EP1976485A4 (en) 2005-12-22 2011-10-26 Celator Pharmaceuticals Inc LIPOSOMAL FORMULATIONS WITH SECONDARY AND TERTIARY AMINES AND METHOD OF MANUFACTURING THEREOF
DK2338487T3 (da) 2006-01-17 2013-12-09 Abbvie Bahamas Ltd Kombinationsterapi med PARP-inhibitorer
US20080146638A1 (en) 2006-01-17 2008-06-19 Abbott Laboratories Combination therapy with parp inhibitors
EP2004175A4 (en) 2006-03-16 2010-12-15 Bionumerik Pharmaceuticals Inc COMPOUNDS AND FORMULATIONS FOR INCREASING THE EFFECT OF CANCER AND METHOD FOR THEIR USE
BRPI0808055A2 (pt) 2007-02-16 2013-07-30 Merrimack Pharmaceuticals Inc anticorpo monoclonal isolado ou porÇço do mesmo que se liga ao antÍgeno, composiÇço, Ácido nucleico isolado, vetor de expressço, cÉlula hospedeira, hibridoma, kit, uso de um anticorpo monoclonal isolado ou porÇço do mesmo que se liga ao antÍgeno, mÉtodo para diagnosticar um cÂncer associado com erbb3 em um paciente, e, anticorpo
WO2008114274A1 (en) 2007-03-19 2008-09-25 Fresenius Kabi Onclology Ltd. Proliposomal and liposomal compositions
US20120003160A1 (en) 2007-06-29 2012-01-05 Amag Pharmaceuticals, Inc. Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session
EP2187869B1 (en) 2007-08-17 2015-10-14 Celator Pharmaceuticals, Inc. Improved platinum drug formulations
CA2700810A1 (en) 2007-09-28 2009-04-02 Universitatsspital Basel Immunoliposomes for treatment of cancer
SG185954A1 (en) 2007-11-12 2012-12-28 Bipar Sciences Inc Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
US20090149397A1 (en) 2007-12-07 2009-06-11 Bipar Sciences Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors
US20110104256A1 (en) 2008-03-25 2011-05-05 Yaolin Wang Methods for treating or preventing colorectal cancer
US8067432B2 (en) 2008-03-31 2011-11-29 University Of Kentucky Research Foundation Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors
EA022201B1 (ru) 2008-04-11 2015-11-30 Мерримак Фармасьютикалз, Инк. Агент, способный связываться с опухолевой клеткой, содержащий линкер на основе hsa, и его применение
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
US8927694B2 (en) 2008-11-18 2015-01-06 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
AU2010234916A1 (en) 2009-03-30 2011-10-13 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
RU2011142806A (ru) 2009-05-01 2013-06-10 ОНКОЗИМ ФАРМА ИНК. (Канада) Комбинации пентамидина для лечения рака
JP5855568B2 (ja) 2009-09-15 2016-02-09 セルリアン・ファーマ・インコーポレイテッド 癌の治療法
CA2782911C (en) 2009-12-03 2016-08-23 Jiangsu Hengrui Medicine Co., Ltd. Liposome of irinotecan or its hydrochloride and preparation method thereof
RU2576609C2 (ru) 2010-06-04 2016-03-10 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечение рака поджелудочной железы
CN107261110A (zh) 2010-06-19 2017-10-20 健康科学西部大学 Peg化脂质体包封的糖肽抗生素的新制剂
MX2013000779A (es) 2010-07-19 2013-07-05 Bipar Sciences Inc Metodos para tratar cancer de mama utilizando 4-yodo-3-nitrobenzamida en combinacion con agentes antitumorales.
RU2598711C2 (ru) 2010-07-22 2016-09-27 Те Риджентс Оф Те Юниверсити Оф Калифорния Антитело к противоопухолевому антигену и способы применения
WO2012031293A1 (en) 2010-09-03 2012-03-08 Board Of Regents Of The University Of Nebraska Compositions and methods for the treatment of cancer
CN107252417A (zh) 2010-12-06 2017-10-17 梅里麦克制药股份有限公司 在使用包含蒽环类化疗剂的erbb2靶向免疫脂质体的治疗中防止心肌毒性的剂量和给药
EP2651447B1 (en) 2010-12-14 2018-08-29 Technical University of Denmark Entrapment of radionuclides in nanoparticle compositions
CA2827118A1 (en) 2011-02-15 2012-08-23 Merrimack Pharmaceuticals, Inc. Compositions and methods for delivering nucleic acid to a cell
CA2833643A1 (en) 2011-04-19 2012-10-26 Merrimack Pharmaceuticals, Inc. Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
WO2013138371A1 (en) 2012-03-12 2013-09-19 Merrimack Pharmaceuticals, Inc. Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody
JP6245481B2 (ja) 2012-04-17 2017-12-13 メリマック ファーマシューティカルズ インコーポレーティッド 非侵襲的イメージングのための組成物および方法
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
CA2882388C (en) 2012-08-31 2020-10-20 Sloan-Kettering Institute For Cancer Research Particles, methods and uses thereof
AU2013374248A1 (en) 2012-12-14 2015-06-11 Merrimack Pharmaceuticals, Inc. Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents
TWI641374B (zh) 2013-03-27 2018-11-21 大鵬藥品工業股份有限公司 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑
EP3038600B1 (en) 2013-08-27 2020-06-03 Northeastern University Nanoparticle drug delivery system and method of treating cancer and neurotrauma
US20160303264A1 (en) 2013-10-23 2016-10-20 Merrimack Pharmaceuticals, Inc. Liposomes useful for non-invasive imaging and drug delivery
EP3229802A1 (en) 2014-12-09 2017-10-18 Ipsen Biopharm Ltd. Treatment of breast cancer with liposomal irinotecan
TW201701880A (zh) 2015-04-14 2017-01-16 莫瑞麥克製藥公司 改善持續釋放藥物治療之藥物動力學及治療指數之方法
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
SG10201913073YA (en) 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
SG10201913077QA (en) 2015-08-21 2020-02-27 Ipsen Biopharm Ltd Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
CN114073678A (zh) 2015-10-16 2022-02-22 易普森生物制药有限公司 稳定喜树碱药物组合物
US20170202840A1 (en) 2016-01-14 2017-07-20 Merrimack Pharmaceuticals, Inc. Treatment of pancreatic cancer with liposomal irinotecan
WO2017172678A1 (en) 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
MX394766B (es) 2016-05-18 2025-03-24 Ipsen Biopharm Ltd Irinotecan nanoliposomico para usarse en el tratamiento del cancer de pulmon de celulas pequeñas.
US20170333421A1 (en) 2016-05-18 2017-11-23 Ipsen Biopharm Ltd. Population Pharmacokinetics of Liposomal Irinotecan
BR112019007844A2 (pt) 2016-11-02 2019-07-16 Ipsen Biopharm Ltd tratamento de câncer gástrico usando terapias de combinação compreendendo irinotecano lipossômico, oxaliplatina, 5-fluoroacila (e leucovorina)

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Chen, Li-Tzong, et al. "Phase I study of biweekly liposome irinotecan (PEP02, MM-398) in metastatic colorectal cancer failed on first-line oxaliplatin-based chemotherapy." Journal of Clinical Oncology 30.4_suppl (2012): 613-613.
LoRusso, P., et al. "Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888; V) in combination with irinotecan (CPT-11; Ir) in patients (pts) with advanced solid tumors." Journal of Clinical Oncology 29.15_suppl (2011): 3000-3000.
LoRusso, Patricia M., et al. "Abstract CT325: Combination of the PARP inhibitor veliparib (ABT888) with irinotecan in patients with triple negative breast cancer: Preliminary activity and signature of response." (2015): CT325-CT325.
Messerer, Corrie Lynn, et al. "Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer." Clinical Cancer Research 10.19 (2004): 6638-6649.
Messerer, Corrie Lynn, et al. "Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer." Clinical Cancer Research 10.19 (2004): 6638-6649. Chen, Li-Tzong, et al. "Phase I study of biweekly liposome irinotecan (PEP02, MM-398) in metastatic colorectal cancer failed on first-line oxaliplatin-based chemotherapy." Journal of Clinical Oncology 30.4_suppl (2012): 613-613. Williams, Sybil M. Genther, et al. "Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status." Cancer cell international 15.1 (2015): 14. LoRusso, Patricia M., et al. "Abstract : Combination of the PARP inhibitor veliparib () with irinotecan in patients with triple negative breast cancer: Preliminary activity and signature of response." (2015): -. LoRusso, P., et al. "Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly (ADP-ribose) polymerase (PARP) inh *
Williams, Sybil M. Genther, et al. "Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status." Cancer cell international 15.1 (2015): 14.

Also Published As

Publication number Publication date
US20200268742A1 (en) 2020-08-27
US20180117034A1 (en) 2018-05-03
EP3337467A1 (en) 2018-06-27
IL257147B (en) 2021-07-29
MX2018001659A (es) 2018-05-28
HK1257249A1 (en) 2019-10-18
RU2018105655A3 (OSRAM) 2020-02-21
PL3337467T3 (pl) 2021-06-14
RU2760185C2 (ru) 2021-11-22
SI3337467T1 (sl) 2021-03-31
JP7042739B2 (ja) 2022-03-28
HK1257216A1 (zh) 2019-10-18
JP2018528184A (ja) 2018-09-27
CA2992789A1 (en) 2017-02-23
EP3337467B1 (en) 2020-12-09
AU2016309002B2 (en) 2021-07-29
US9895365B2 (en) 2018-02-20
MX381475B (es) 2025-03-12
IL257147A (en) 2018-03-29
US20170049767A1 (en) 2017-02-23
SG10201913073YA (en) 2020-03-30
TW201713312A (zh) 2017-04-16
US10478428B2 (en) 2019-11-19
KR20180037210A (ko) 2018-04-11
US11844795B2 (en) 2023-12-19
AU2016309002A1 (en) 2018-02-08
CN108348480A (zh) 2018-07-31
RU2018105655A (ru) 2019-09-23
US20230074866A1 (en) 2023-03-09
WO2017031445A1 (en) 2017-02-23
ES2848118T3 (es) 2021-08-05
PT3337467T (pt) 2021-01-25
WO2017031442A1 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
TWI724018B (zh) 用於癌症治療之組合療法
Chang et al. Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
Rubin et al. A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar. 3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies
Boulikas Molecular mechanisms of cisplatin and its liposomally encapsulated form, Lipoplatin™. Lipoplatin™ as a chemotherapy and antiangiogenesis drug
JP2019116517A (ja) リポソームイリノテカンを含む併用療法を用いた、膵臓癌を治療するための方法
TW202508602A (zh) 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法
AU2017354903A1 (en) Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
WO2017172678A1 (en) Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
Burris et al. A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle
Gelmon et al. A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers
CA2437768A1 (en) Targetted anti-tumor drug delivery systems
Murakami et al. ZD0473 pharmacokinetics in Japanese patients: a Phase I dose-escalation study
Tada et al. A single institutional subset analysis of the WJLCG study comparing concurrent and sequential chemoradiotherapy for stage III non-small-cell lung cancer
HK1257249B (en) Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
US20240350497A1 (en) Combination therapy for the treatment of pan-kras mutated cancers
Curtis et al. A Phase I Study to Characterize the Safety, Tolerability, and Pharmacokinetics of Topotecan at 4 mg/m2 Administered Weekly as a 30‐Minute Intravenous Infusion in Patients With Cancer
Puls et al. Effect of topotecan infusion duration on hematologic toxicity in recurrent ovarian carcinoma
Nitschmann Anti-neoplastic Activity of Topoisomerase I Inhibitor Etirinotecan Pegol (NKTR-102) and PARP Inhibitor Rucaparib (CO-388) Against Ovarian Cancer Patient Derived Xenograft Models
White Novel Forms of Platinum Therapy in Lung Cancer